Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion type Assertion NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_head.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion description "[Therefore, inhibitors of transglutaminase 2 should be considered as possible therapeutics for OPMD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_provenance.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion evidence source_evidence_literature NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_provenance.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion SIO_000772 20519718 NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_provenance.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion wasDerivedFrom befree-20150227 NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_provenance.
- NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_assertion wasGeneratedBy ECO_0000203 NP735038.RAnDfCo4SVkd3GMVl6tP-oQCfCeOLS3isdyyENTmfEhpA130_provenance.